CUMYL-PICA

CUMYL-PICA
Legal status
Legal status	CA: Schedule II ; DE: NpSG (Industrial and scientific use only) ; UK: Under Psychoactive Substances Act ;
Identifiers
	IUPAC name 1-pentyl-N-(2-phenylpropan-2-yl)-1H-indole-3-carboxamide;
CAS Number	1400742-32-6;
PubChem CID	86273678;
ChemSpider	34450887;
Chemical and physical data
Formula	C23H28N2O
Molar mass	348.49 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(NC(C)(C)C1=CC=CC=C1)C2=CN(CCCCC)C3=C2C=CC=C3;
	InChI InChI=1S/C23H28N2O/c1-4-5-11-16-25-17-20(19-14-9-10-15-21(19)25)22(26)24-23(2,3)18-12-7-6-8-13-18/h6-10,12-15,17H,4-5,11,16H2,1-3H3,(H,24,26); Key:RCXFMWJQOYCIQU-UHFFFAOYSA-N;

CUMYL-PICA (SGT-56) is an indole-3-carboxamide based synthetic cannabinoid. It is the α,α-dimethylbenzyl analogue of SDB-006.[1] It was briefly sold in New Zealand during 2013 as an ingredient of at the time legal synthetic cannabis products, but the product containing CUMYL-BICA and CUMYL-PICA was denied an interim licensing approval under the Psychoactive Substances regulatory scheme, due to reports of adverse events in consumers.[2] CUMYL-PICA acts as an agonist for the cannabinoid receptors, with K_i values of 59.21 nM at CB₁ and 136.38 nM at CB₂ and EC₅₀ values of 11.98 nM at CB₁ and 16.2 nM at CB₂.[3][4]

References

"CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.
"The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013" (PDF). Archived from the original (PDF) on 2014-01-08. Retrieved 2015-07-09.
Gamage, Thomas F.; Farquhar, Charlotte E.; Lefever, Timothy W.; Marusich, Julie A.; Kevin, Richard C.; McGregor, Iain S.; Wiley, Jenny L.; Thomas, Brian F. (April 2018). "Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA". Journal of Pharmacology and Experimental Therapeutics. 365 (1): jpet.117.246983. doi:10.1124/jpet.117.246983. ISSN 0022-3565. PMC 5932312. PMID 29549157.
Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "CUMYL-PICA". Cayman Chemical. Retrieved 8 July 2015.

[2] "The Risk Assessment Score Table. New Zealand Ministry of Health, 27 September 2013" (PDF). Archived from the original (PDF) on 2014-01-08. Retrieved 2015-07-09.

[3] Gamage, Thomas F.; Farquhar, Charlotte E.; Lefever, Timothy W.; Marusich, Julie A.; Kevin, Richard C.; McGregor, Iain S.; Wiley, Jenny L.; Thomas, Brian F. (April 2018). "Molecular and behavioral pharmacological characterization of abused synthetic cannabinoids MMB- and MDMB-FUBINACA, MN-18, NNEI, CUMYL-PICA, and 5-fluoro-CUMYL-PICA". Journal of Pharmacology and Experimental Therapeutics. 365 (1): jpet.117.246983. doi:10.1124/jpet.117.246983. ISSN 0022-3565. PMC 5932312. PMID 29549157.

[4] Bowden; et al. (11 April 2013). "Patent WO 2014167530 - Cannabinoid compounds". New Zealand Patent application 623626. Retrieved 11 July 2015.

CUMYL-PICA

See also

References